Meng Jia, Cai Shan-Jun
Department of Ophthalmology, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Guizhou Eye Hospital, Zunyi, China.
Front Physiol. 2025 Jul 1;16:1623185. doi: 10.3389/fphys.2025.1623185. eCollection 2025.
Hereditary transthyretin amyloidosis (ATTRv) results from genetic mutations that destabilize transthyretin (TTR), leading to the formation of extracellular aggregates and amyloid fibrils. A common pathological feature of ATTRv is the capacity of TTR variants to evade endoplasmic reticulum quality control (ERQC) and be secreted, underscoring the critical role of ER regulation in disease pathogenesis. Notably, the TTR Gly83Arg mutation causes familial vitreous amyloidosis, a subtype distinguished by abnormal TTR deposition in the ocular vitreous cavity. Current therapies for ATTRv are ineffective in crossing the blood-retinal barrier or in halting the progression of ocular amyloidosis. This review summarizes the molecular mechanisms of ER-regulated TTR secretion and explores potential causes of ocular amyloid deposition, aiming to provide mechanistic insights into familial vitreous amyloidosis.
遗传性转甲状腺素蛋白淀粉样变性(ATTRv)由使转甲状腺素蛋白(TTR)不稳定的基因突变引起,导致细胞外聚集体和淀粉样原纤维的形成。ATTRv的一个常见病理特征是TTR变体逃避内质网质量控制(ERQC)并被分泌的能力,这突出了内质网调节在疾病发病机制中的关键作用。值得注意的是,TTR Gly83Arg突变会导致家族性玻璃体淀粉样变性,这是一种以TTR在眼玻璃体腔中异常沉积为特征的亚型。目前针对ATTRv的治疗方法在跨越血视网膜屏障或阻止眼淀粉样变性进展方面无效。本综述总结了内质网调节的TTR分泌的分子机制,并探讨了眼淀粉样沉积的潜在原因,旨在为家族性玻璃体淀粉样变性提供机制性见解。